4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 StudyByJamil Asselah,Cynthia X. Ma, MD, PhD,Zbigniew Nowecki,Robert Huisden,Ross Stewart,Petra Vuković,Peter Schmid, MDApril 28th 2023
